July | August 2009

New Warnings for Botulinum Toxin Products
The United States Food & Drug Administration has announced new safety label changes for all botulinum toxin products. Four FDA-approved products—Botox, Botox Cosmetic, Myobloc and Dysport—are now required to include a boxed warning and a Risk Evaluation and Mitigation Strategy (REMS) for healthcare professionals and patients. The action was prompted by reports of serious adverse events relating to the spread of botulunum toxin from the area of injection to other areas of the body.

The FDA urges healthcare professionals who use botulinum toxins to:

• Understand that dosage strength expressed in “units” is different among the botulinum products and therefore not interchangeable from one product to another.
• Be alert to and educate patients and caregivers about the potential effects following injection, including unexpected loss of strength or muscle weakness, hoarseness or trouble speaking clearly, trouble breathing or swallowing, double or blurred vision, and drooping eyelids.
• Understand that these effects have been reported as early as several hours and as late as several weeks after treatment.
• Advise patients to seek immediate medical attention if they develop any of these symptoms.

Palomar To Distribute Quantel Device
Palomar Medical Technologies, a leading researcher and developer of light-based devices, will distribute Quantel's SINON Q-switched ruby laser for tattoo removal in the United States and Canada. Palomar entered into a distribution agreement with Eriangen, Germany-based Quantel Derma, a manufacturer of solid state lasers, in May 2009. As part of the agreement, the SINON will be exclusively marketed in the U.S. and Canada by Palomar. Installation and technical support will be provided by Quantel USA, based in Bozeman, Montana. "We are pleased to become the exclusive distributor for Quantel Derma's SINON," said Joseph Caruso, CEO, Palomar. "With the shortest pulse and highest peak power of all ruby lasers available, the SINON is optimized to treat the more complex and difficult to remove tattoos you see today."

Beta-Blockers and Hemangioma Trials Set
Pierre Fabre Dermatologie has announced the launch of a set of clinical trials to ascertain the efficacy of beta-blockers in the treatment of hemangioma. The launch of the clinical trials follows the signing of an exclusive, worldwide license agreement between Pierre Fabre and the University of Bordeaux. The agreement covers the development, production and marketing of a pediatric beta-blocker for the treatment of severe infantile hemangioma. "This is a major discovery that will bring true therapeutic advances to patients affected by this highly apparent disease, which can be very severe and can have a strong impact on the child's quality of life and that of the parents," said Jacques Fabre, general manager of Pierre Fabre Dermocosmétique.

UV Photographs Improve Sun Protection Compliance
Research shows that teens who see UV photographs illustrating their existing sun damage and pigment changes, not visible to the naked eye, are more likely to follow proper sun protection protocol. The study, performed by the Boston University School of Medicine and partially funded by the LaRoche-Posay North American Foundation, followed 111 students between the ages of 11 and 13 years old for six months. All students were informed of proper sun protection protocol, 83 of the subjects received an additional intervention, consisting of their own UV photographs. According to researchers, the intervention group reported 36% fewer sunburns at two months and 51% fewer sunburns than the control group at six months. "The UV photographs represent an immediate picture of sun damage that can impact impressionable teens," said Marie-France Demierre, MD, lead researcher.

Clarisonic Supports Breast Cancer Research
Clarisonic donated $200,000 to the 16th Annual Entertainment Industry Foundation Revlon Run/Walk for Women. More than 50,000 participants took part in the event, held in Los Angeles on May 9, 2009. The money was raised as part of Clarisonic's "Pink Ribbon" campaign, which donates a portion of the sales of the Pink Clarisonic Skin Cleansing System to help fight breast cancer. Since its inception in 2007, the campaign has raised more than $400,000. "Nearly everyone in the country has been touched by breast cancer in some way—if not personally, then through a friend or loved one," said David Giuliani, CEO, Pacific Biosciences Laboratories, makers of the Clarisonic. "In the shared spirit of the thousands of runners, walkers and supporters who have come out today, it is our hope that this donation will help in the fight against breast cancer."

Chrysallis CEO Melisse Shaban accepts the 2009 Indie Beauty Award from Allure magazine’s Linda Wells for the NIA 24 line.

NIA 24 Honored
Niadyne, makers of NIA 24 Niacin-Powered Skin Therapy, was awarded the 2009 Indie Beauty Award, which recognizes innovation and entrepreneurial spirit in up-and-coming niche beauty brands. The annual award is bestowed upon recipients by Cosmetic Executive Women (CEW), a nonprofit, professional organization comprised of more than 4,000 cosmetic industry executives. Launched in 2006, NIA 24 is a science-based, physician-recommended line that was developed through funding from the National Institutes of Health and researched at the University of Arizona Cancer Institute. "We're thrilled to receive this extraordinary honor from the CEW," said Melisse Shaban, CEO of Chrysallis, the management group that operates Niadyne. "This is an amazing endorsement of the science of our company's products from leading experts in the cosmetics industry."

SkinMedica Joins Forces With Allergan
SkinMedica has entered into an agreement with Allergan to exclusively promote Allergan's ACZONE Gel 5% to pediatricians in the United States. ACZONE Gel 5%, a topical treatment for acne in patients 12 years of age and older, combines dapsone in a Solvent Microparticulate gel, enabling dapsone to be topically applied in a well-tolerated formulation. It is the first new molecule approved by the U.S. Food and Drug Administration for the topical treatment of acne in a decade. "We are delighted to add ACZONE Gel 5% to our dermatology consultations with pediatricians, as it provides us with a pivotal opportunity to further educate pediatricians on the latest advances in acne treatments," said Mary Fisher, president/CEO of SkinMedica.

Correction
In the May/June 2009 feature "Scratching the Surface," the images shown above were incorrectly credited. These changes in skin tone and texture were obtained with the Edge Systems Hydrafacial MD.

Events

July 11-13
Face & Body Spa & Healthy Aging Conference & Expo, McEnery Convention Center, San Jose, California.
Contact: 630.653.2155, faceandbody.com

July 22-26
17th Annual Scientific Meeting of the International Society of Hair Restoration Surgery, RAI Convention Centre, Amsterdam, The Netherlands.
Contact: 630.262.5399, ishrs.org

July 29-August 2
American Academy of Dermatology Summer Meeting, Boston, Massachusetts, Venue TBA.
Contact: 866.503.7546, aad.org

August 14-15
Brazil Congress on Anti-Aging Medicine, Palacio das Convencoes Anhembi, Sao Paulo, Brazil.
Contact: 888.997.0112, worldhealth.net

September 10-12
17th Annual World Congress on Anti-Aging Medicine, San Jose Convention Center, San Jose, California. Contact: 888.997.0112, wwww.worldhealth.net

September 12-15
International Congress of Esthetics and Spa, Long Beach Convention Center, Long Beach, California. Contact: www.lneonline.com

September 15-16
Medical Aesthetics Conference & Expo, Jacob K. Javits Convention Center, New York City. Contact: 888.267.3793, www.medaestheticsconferenceny.com

October 1-4
American Society for Dermatologic Surgery and American Society of Cosmetic Dermatology & Aesthetic Surgery Joint Annual Meeting, JW Marriot Desert Ridge Resort & Spa, Phoenix. Contact: 847.956.0900, www.asds.net

October 2-3 5th Annual European Masters in Anti-Aging & Aesthetic Medicine, Palais des Congrés of Paris, Paris, France.
Contact: EMAA, euromedicom.com

October 5-8
2009 ISPA Conference & Expo, Austin Convention Center, Austin, Texas. Contact: 888.651.4772,
www.asds.net

October 15-17
European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM), The Congress Centre Mainz, Frankfurt, Germany. Contact: Matt Thompson, mthompson@tarsus.co.uk, http://germany.anti-agingevents.com

October 23-28
35th Annual Convention of the American Society of Plastic Surgical Nurses, Grand Hyatt Seattle, Seattle. Contact: 800.272.0136, aspsn.org

October 23-28
Plastic Surgery 2009, Washington State Convention Center, Seattle. Contact: ASPS, 847.228.9900, plasticsurgery.org

December 9-12
17th Annual World Congress on Anti-Aging Medicine, Mandalay Bay Hotel & Casino, Las Vegas. Contact: 888.997.0112, worldhealth.net